BCR-ABL: A multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia

Leukemia

Volumn 24, Issue 6, 2010, Pages 1105-1112

  Burke, B A ^a   Carroll, M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BCR ABL; blast crisis; chronic myeloid leukemia; DNA damage

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ATM PROTEIN; ATR PROTEIN; BCR ABL PROTEIN; BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MISMATCH REPAIR PROTEIN PMS2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P21; PROTEIN P53; DNA;

APOPTOSIS; BLAST CELL CRISIS; CANCER GROWTH; CELL PROLIFERATION; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA END JOINING REPAIR; DNA REPAIR; DNA STRAND BREAKAGE; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HYPERTROPHY; MISMATCH REPAIR; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECOMBINATION REPAIR; REVIEW; SINGLE STRAND ANNEALING; SINGLE STRANDED DNA BREAK; SPECTRAL KARYOTYPING; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; PROMOTER REGION;

DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 77954594460     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.67     Document Type: Review

References (60)

1. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792. (Pubitemid 28525205)
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. (Pubitemid 32267972)
3. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 20-34.
4. Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80: 1788-1797.
5. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 2000; 14: 1401-1404. (Pubitemid 30599320)
6. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC et al. Down-regulation of BRCA1 in BCR-ABLexpressing hematopoietic cells. Blood 2003; 101: 4583-4588. (Pubitemid 36857831)
7. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR//ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008; 22: 1969-1972.
8. Dierov J, Sanchez PV, Burke BA, Padilla-Nash H, Putt ME, Ried T et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 2009; 23: 279-286.
9. Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008; 49: 610-614. (Pubitemid 351517197)
10. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717-1723. (Pubitemid 40223695)
11. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces selfmutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319-327. (Pubitemid 43990645)
12. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273-24278. (Pubitemid 30626515)
13. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232-245.
14. Kunkel TA, Bebenek K. DNA replication fidelity. Annu Rev Biochem 2000; 69: 497-529.
15. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137. (Pubitemid 41291730)
16. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001; 293: 876-880. (Pubitemid 32743979)
17. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
18. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
19. Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576-2580. (Pubitemid 351556254)
20. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632-2637. (Pubitemid 37193605)
21. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M et al. Impact of p210(Bcr-Abl) on ultraviolet C wavelengthinduced DNA damage and repair. Clin Cancer Res 2003; 9: 3722-3730. (Pubitemid 37169241)
22. Maru Y, Kobayashi T, Tanaka K, Shibuya M. BCR binds to the xeroderma pigmentosum group B protein. Biochem Biophys Res Commun 1999; 260: 309-312. (Pubitemid 29352062)
23. Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 1999; 96: 203-207. (Pubitemid 29036077)
24. Maru Y, Bergmann E, Coin F, Egly JM, Shibuya M. TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat Res 2001; 483: 83-88. (Pubitemid 33000069)
25. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004; 5: 275-285. (Pubitemid 38402119)
26. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-234. (Pubitemid 32148491)
27. Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006; 5: 994-1000.
28. Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat Res 2008; 654: 162-167.
29. Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair 2006; 5: 243-250. (Pubitemid 43069524)
30. Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791-2797. (Pubitemid 34525762)
31. Pastwa E, Poplawski T, Czechowska A, Malinowski M, Blasiak J. Non-homologous DNA end joining repair in normal and leukemic cells depends on the substrate ends. Z Naturforsch (C) 2005; 60: 493-500. (Pubitemid 40968484)
32. Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001; 97: 2084-2090. (Pubitemid 32239090)
33. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003; 63: 1798-1805. (Pubitemid 36460840)
34. Corneo B, Wendland RL, Deriano L, Cui X, Klein IA, Wong SY et al. Rag mutations reveal robust alternative end joining. Nature 2007; 449: 483-486. (Pubitemid 47509551)
35. Gottlich B, Reichenberger S, Feldmann E, Pfeiffer P. Rejoining of DNA double-strand breaks in vitro by single-strand annealing. Eur J Biochem/FEBS 1998; 258: 387-395. (Pubitemid 28557902)
36. Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res 2005; 65: 4020-4030. (Pubitemid 40775638)
37. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006; 34: 6170-6182. (Pubitemid 44942738)
38. Oshima J, Huang S, Pae C, Campisi J, Schiestl RH. Lack of WRN results in extensive deletion at nonhomologous joining ends. Cancer Res 2002; 62: 547-551. (Pubitemid 34106430)
39. Sallmyr A, Tomkinson AE, Rassool FV. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 2008; 112: 1413-1423.
40. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746-3753. (Pubitemid 39564453)
41. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189-4201. (Pubitemid 34556589)
42. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B et al. Radiationinduced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748-12752.
43. Benson FE, Baumann P, West SC. Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature 1998; 391: 401-404. (Pubitemid 28093516)
44. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795-806. (Pubitemid 33030213)
45. Langland G, Elliott J, Li Y, Creaney J, Dixon K, Groden J. The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Res 2002; 62: 2766-2770. (Pubitemid 34525759)
46. Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J et al. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene 2005; 24: 3914-3922. (Pubitemid 40896403)
47. Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008; 68: 6884-6888.
48. Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009; 114: 1813-1819.
49. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519. (Pubitemid 27235471)
50. Melo JV, Kumberova A, van Dijk AG, Goldman JM, Yuille MR. Investigation on the role of the ATM gene in chronic myeloid leukaemia. Leukemia 2001; 15: 1448-1450. (Pubitemid 32785315)
51. Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P et al. p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 2004; 15: 3751-3757. (Pubitemid 38989712)
52. Marx J. Cell biology. Do centrosome abnormalities lead to cancer? Science (New York) 2001; 292: 426-429.
53. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev 2001; 2: 21-32. (Pubitemid 33676958)
54. Giehl M, Fabarius A, Frank O, Erben P, Zheng C, Hafner M et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia 2007; 21: 1971-1976. (Pubitemid 47299972)
55. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005; 19: 1192-1197. (Pubitemid 40946003)
56. Martin SJ, Lennon SV, Bonham AM, Cotter TG. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990; 145: 1859-1867. (Pubitemid 20336755)
57. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187. (Pubitemid 24062839)
58. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998; 16: 1383-1390. (Pubitemid 28151845)
59. Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001; 15: 1823-1833. (Pubitemid 33114987)
60. Keeshan K, Cotter TG, McKenna SL. High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002; 16: 1725-1734.